Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

NCT03980041 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Bladder Cancer
Urothelial Carcinoma
Solid Tumor
Advanced Cancer

Interventions

DRUG: IPI-549 (eganelisib)
DRUG: Nivolumab
DRUG: Placebos

Sponsor

Infinity Pharmaceuticals, Inc.

Collaborators

[object Object]